Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Feb 26, 2021; 9(6): 1329-1335
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1329
Figure 3
Figure 3 The patient’s clinical course including treatment history and relevant imaging studies. A: At baseline before therapy with afatinib combined with bevacizumab; B: At 4 mo of therapy with afatinib combined with bevacizumab, with an SD response; C: At 14 mo of therapy with afatinib combined with bevacizumab, with an SD response. D: At 17 mo of therapy with afatinib combined with bevacizumab, with a progressive disease response.